CNI103 , CAS No.2366279-86-7

CAS: 2366279-86-7 Cat. No.: C1438761 Formula: C₁₁₆H₁₈₀Cl₂N₃₆O₂₆ Molecular Weight: 2565.80

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Overview

CNI103 is a highly potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. CNI103 selectively blocks the interaction between calcineurin and NFATc3 ( K D =16 nM), thereby preventing NFATc3 activation in vitro and in vivo. CNI103 can be used to study acute respiratory distress syndrome (ARDS) and other inflammatory diseases.

Specifications

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Names and Identifiers

Molecular Weight

2565.80

Application Protocols

No application protocols are specified for CNI103 in this listing. As a general guide for small-molecule screening:

• Stock solutions: prepare at 10–50 mM in dry DMSO; vortex/sonicate to dissolve. Filter if necessary using solvent-compatible membranes.
• Plating: dispense with acoustic or pin tools where available; include vehicle controls matched to final solvent percentage.
• Assays: validate a concentration range (e.g., 10-point 3-fold serial dilution) and confirm absence of compound precipitation or assay interference.
• Analytics: confirm identity/purity post-screen from the same lot to ensure hit validity (LC–MS, 1H NMR).

Refer to your institutional SOPs and the product’s CoA/SDS.

Biological Roles

The specific biological roles or target interactions of CNI103 are not provided. As a coded small-molecule library member, any biological activity must be established experimentally by the end user.

General considerations for screening compounds

• Treat CNI103 as a putative probe candidate only after confirming identity and purity, determining solubility, and evaluating stability in assay media.
• Assess liabilities common to screening hits (aggregation, redox cycling, fluorescence/absorbance interference, metal chelation, and PAINS motifs) once the structure is known.
• Use orthogonal assays (biochemical vs cell-based) and counterscreens to rule out assay artifacts.

Note: No medical or clinical claims are made. For research use only.

Buffer Applications

CNI103 is a small-molecule screening compound, not a buffering agent. Specific buffer systems or buffering capacities are not applicable.

Practical note

• When dosing from DMSO stocks into biological buffers, maintain DMSO at the lowest compatible percentage and verify that the compound remains solubilized (visual check for precipitation; optional nephelometry). Adjust ionic strength or include acceptable co-solvents/surfactants only if validated for the assay.

Green Alternatives

Without structural details, solvent and process choices for CNI103 cannot be optimized specifically. The following general green-chemistry guidance applies to handling small molecules in screening and sample preparation.

Greener stock/dilution strategies

• Prefer aqueous-compatible systems to minimize DMSO where assay-appropriate (e.g., DMSO ≤0.5% v/v in final wells).
• Use ethanol or isopropanol for cleaning and intermediate handling where compatible, reducing chlorinated solvent use.

Comparison of common solvents (general, literature)

• DMSO: high solvency, water-miscible; not “green” but efficient for small amounts. Tradeoff: potential biological interference at higher %.
• MeOH/EtOH/IPA: relatively greener, good for polar/medium-polar compounds; flammable.
• 2-MeTHF/CPME/EtOAc: greener options for extractions or preparative work compared with THF/diethyl ether or chlorinated solvents, subject to solubility.

Operational tips

• Use microscale assays to reduce chemical consumption and waste.
• Consolidate shipping and storage to minimize cold-chain emissions while maintaining product integrity.

Always align choices with your institution’s green chemistry guidelines and assay constraints.

Pharmaceutical Uses

No excipient or pharmacopeial status is provided for CNI103. It is supplied strictly for research use only and not for human or veterinary applications.

Formulation context (research only)

• For in vitro studies, prepare DMSO or ethanol stocks and dilute into assay media, confirming absence of precipitation and acceptable vehicle controls.
• For exploratory in vivo research performed under appropriate approvals, users must establish formulation, stability, and safety de novo; no claims or guidance are provided here.

Regulatory note

• This product is not accompanied by GMP certification, pharmacopeial monographs, or clinical-use authorization. Refer to the CoA/Spec Sheet for any available quality attributes.

Physical Properties

As the specific chemical structure for CNI103 is not disclosed here, definitive physicochemical specifications cannot be listed.

Item-specific properties

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.
• logP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.

Practical guidance (general, literature-based)

• For unknown small molecules, begin with a 10–50 mM DMSO stock and perform a small solubility screen (DMSO, DMF, MeOH, water with co-solvent, pH adjustments if ionizable).
• If the compound contains potential peroxide-forming motifs (ethers, enolizable dienes), evaluate stability upon storage; otherwise, default to dry, cold, and protected-from-light storage.
• Measure an indicative UV-Vis spectrum to assist with concentration determinations and to anticipate interference in optical assays.
• If crystalline, a DSC/TGA scan can reveal melting behavior and thermal stability ranges; for oils, variable-temperature 1H NMR can help assess volatility and aggregation.

Always defer to the product’s CoA/SDS for authoritative values and handling limits.

Quality & Grades

Grade/purity information is not specified for this item; refer to CoA/Spec Sheet.

Guidance on interpreting grades (general)

• Screening-library compounds are commonly supplied at assay or research grade and may be accompanied by LC–MS purity (often area% by UV at a specified wavelength) and, when applicable, 1H NMR identity confirmation. These details are item-specific and must be verified on the CoA.
• If the material includes salt form, solvate, or polymorph information, confirm equivalence to the intended form used in published assays.

What to check on receipt

• Purity method and threshold (e.g., LC–MS ≥95% by UV). Not specified for this item; refer to CoA/Spec Sheet.
• Residual solvents, water content (Karl Fischer), and counterion content if a salt. Not specified for this item; refer to CoA/Spec Sheet.
• Identity confirmation (MS, NMR) and lot traceability.

Stabilizers/additives

• Presence or absence of stabilizers is not specified for this item; refer to CoA/Spec Sheet. If stabilizers are present, consider their impact on bioassays (UV background, reactivity) and analytical measurements.

Reaction & Applications

CNI103 is supplied as a research screening compound rather than a general-purpose synthetic reagent. In the absence of a disclosed structure or functional group information, specific reaction chemistry cannot be recommended.

• Primary use case: inclusion in small-molecule libraries for target-agnostic or targeted screening, SAR exploration, and chemical biology tool development.
• Assay contexts: enzymatic inhibition/activation screens, phenotypic assays, or binding measurements, subject to users’ validation.

If repurposing for synthesis (general guidance)

• Do not assume reactivity or compatibility without structural information. Acquire NMR and LC–MS to confirm identity and assess functional handles.
• Conduct micro-scale test reactions to evaluate stability under typical conditions (acid/base, oxidation/reduction, metal catalysis) only after the structure is known.

Reporting

• Document lot number, solvent, concentration, and any pre-treatments (drying, neutralization) in ELNs to ensure reproducibility across screens.

Reaction Conditions

No reaction conditions can be prescribed for CNI103 without structural information. If repurposing for chemistry after the structure is disclosed, follow these general steps.

General workflow

• Analytical confirmation: LC–MS and 1H/13C NMR to establish identity and assess purity. Determine moisture content if hydrolytically sensitive motifs are suspected.
• Small-scale scouting: evaluate stability to acid/base, reductants/oxidants, and heating (e.g., 40–120°C) in common solvents (MeOH, MeCN, toluene, dioxane) as appropriate to functional groups.
• Catalysis: choose catalysts/ligands only after confirming reactive sites (e.g., Pd for cross-coupling of aryl halides, Cu for Ullmann-type couplings, etc.).

Documentation

• Record exact solvent grade, concentrations, temperature profiles, and atmosphere (air vs inert) for reproducibility.

Safety & Handling

Hazard and GHS information for CNI103 is not provided in this listing. Handle as a research chemical of unknown hazards.

Item-specific safety data

• Signal word: Not specified for this item; refer to SDS.
• H-statements: Not specified for this item; refer to SDS.
• GHS classification/pictograms: Not specified for this item; refer to SDS.

General laboratory precautions

• Use standard PPE: lab coat, nitrile gloves, and chemical splash goggles. Work in a fume hood to avoid inhalation exposure and to control vapors/aerosols.
• Avoid contact with skin and eyes; prevent ingestion and inhalation. Keep away from strong oxidizers, strong acids/bases, and ignition sources until reactivity is known.
• Upon exposure: rinse skin/eyes with water for ≥15 minutes; move to fresh air if inhaled; seek medical attention as needed. Provide the SDS to responders.

Special considerations for unknowns

• Assume potential solvency in DMSO; minimize dermal exposure due to possible rapid transdermal transport.
• If heating or drying, use small test portions and monitor for decomposition (discoloration, gas evolution). Do not seal in pressure-tight containers without venting.

Always consult the SDS and institutional EHS policies before use. For research use only.

Solvent Selection

The optimal solvent for CNI103 cannot be prescribed without its structure. The following decision framework is provided for efficient solubility scouting of small molecules in screening workflows.

Recommended sequence

• Stock preparation: attempt 10–50 mM in anhydrous DMSO at room temperature with gentle warming/sonication as needed.
• If partial solubility: consider DMF, NMP, or MeOH as alternative stock solvents; avoid strong bases/acids unless the compound’s ionization state is known.
• Aqueous use: dilute DMSO stocks into assay buffers keeping final DMSO ≤0.5–1% v/v (or per assay tolerance). Add co-solvent (0.01–0.1% Tween-80 or Pluronic) only if compatible with the assay.

Miscibility/polarity (general)

• DMSO is miscible with water and many organics and is typically the first choice for unknown small molecules.
• For very nonpolar compounds, use IPA, EtOH, or PEG400 co-solvent systems.

Analytical notes

• Filter through low-binding PTFE/NYLON (if solvent-compatible) to remove particulates. Verify concentration by UV-Vis or quantitative 1H NMR where feasible.

Storage & Reconstitution

Storage and shipping

• Storage conditions: Store at -20°C (per product data). Keep container tightly closed. Protect from moisture; protect from light unless otherwise indicated on the label.
• Shipped in: Ice chest + ice pads (per product data) to maintain cold chain.

Reconstitution (general guidance for small molecules)

• Allow vial to equilibrate to room temperature in a desiccated environment before opening to prevent condensation.
• Prepare concentrated stocks (e.g., 10–50 mM) in anhydrous DMSO unless the CoA specifies a preferred solvent. If insoluble, trial DMF, NMP, or MeOH.
• Aliquot stocks to minimize freeze–thaw cycles. Store aliquots at -20°C or below. Avoid frost-free freezers that undergo warm cycles.

Stability notes

• Item-specific stability, hygroscopicity, and light sensitivity: Not specified for this item; refer to CoA/Spec Sheet.
• Inspect periodically for precipitation, discoloration, or evaporation. Discard if degradation is suspected.

For research use only.

Structure & Identity

This product is offered as a coded small-molecule library member (internal code: CNI103). Item-specific structural identifiers have not been provided in the current listing.

• Chemical name: Not specified for this item; refer to CoA/Spec Sheet.
• CAS: 2366279-86-7
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• 2D structure: Not specified for this item; refer to CoA/Spec Sheet.

Notes

• CNI103 is part of a curated small-molecule/compound library intended for research screening and chemical biology. Without the explicit structure, users should rely on the item’s CoA/SDS for definitive identity and characterization.
• If a structure becomes available, record all identifiers (SMILES, InChIKey, MF, MW) in your ELN and cross-check with LC–MS/NMR data prior to use in assays.

Synthetic Utility

CNI103 is provided as a screening library compound rather than a defined synthetic intermediate. Without knowledge of its functional groups, specific transformations or named-reaction applicability cannot be recommended.

General guidance if structure becomes available

• Map functional handles (e.g., aryl halides, boronates, amines, acids, alcohols) to standard cross-couplings (Suzuki, Buchwald–Hartwig), amide couplings, or protection–deprotection strategies.
• If chiral, verify enantiopurity and consider asymmetric synthesis or resolution routes for SAR expansion.
• For analog development, identify liabilities (metabolic soft spots, hydrolysis-prone motifs) and design robust bioisosteres.

Until structural data are provided, treat CNI103 primarily as a test article for screening, not as a building block.

Target Specificity

Target, epitope, or biochemical specificity data are not provided for CNI103. There are no antibody/biologic attributes associated with this product, and no target engagement claims are made. Any specificity must be determined experimentally by the end user using appropriate assays (binding, enzymatic activity, thermal shift, CETSA, SPR, ITC, etc.).

Frequently Asked Questions

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2366279-86-7, the molecular formula is C116H180Cl2N36O26, and the molecular weight is 2565.80 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.